# A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

> **NCT06328673** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **D2M Biotherapeutics Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** DM919
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06328673
- **Lead sponsor:** D2M Biotherapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-04-09
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328673, "A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT06328673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*